On April 12, 2019, the Board of Directors of Allena Pharmaceuticals, Inc. appointed Allene Diaz to the Board, effective April 15, 2019. Ms. Diaz will serve as a Class II director with a term expiring at the company’s next annual meeting of stockholders, which is expected to be held on June 5, 2019 (the “Annual Meeting”), and until such time as her successor is duly elected and qualified, or until her earlier death, resignation or removal. Allene Diaz has served as the Senior Vice President of Global Commercial Development and Program Strategy at TESARO, Inc. since May 2015. She currently serves as an independent director of Erytech Pharma SA. Following the appointment of Ms. Diaz, Class II directors consist of Louis Brenner, M.D., Axel Bolte, Allene Diaz and Robert Tepper, M.D. The terms for Class II directors will expire at the Annual Meeting. On April 12, 2019, Axel Bolte notified the company that he will not stand for reelection at the Annual Meeting.